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Transdermal patches: Design and current approaches 
to painless drug delivery
Use of transdermal patches can evade many issues associ-
ated with oral drug delivery, such as first-pass hepatic 
metabolism, enzymatic digestion attack, drug hydrolysis 
and degradation in acidic media, drug fluctuations, and 
gastrointestinal irritation. This article reviews various 
transdermal patches available in the market, types, struc-
tural components, polymer role, and the required assess-
ment tools. Although transdermal patches have medical 
applications for smoking cessation, pain relief, osteoporo-
sis, contraception, motion sickness, angina pectoris, and 
cardiac disorders, advances in formulation development 
are ongoing to make transdermal patches capable of de-
livering more challenging drugs. Transdermal patches 
can be tailored and developed according to the physico-
chemical properties of active and inactive components, 
and applicability for long-term use. Therefore, a number 
of chemical approaches and physical techniques for 
transdermal patch development are under investigation.
Keywords: transdermal patch, transdermal drug delivery, 
polymer matrix, adhesives, skin formulation
INTRODUCTION
Development of a safe and efficient drug delivery system is the aim of every pharma-
ceutical researcher and industry (1). Transdermal route of drug delivery can achieve local 
and systemic therapeutic effects (2). Transdermal drug delivery is an attractive substitute 
for oral drug administration as it bypasses first pass metabolism, gastrointestinal effects 
and, moreover, it can overcome the poor patient compliance associated with other drug 
delivery routes (3–6). Transdermal drug delivery is self-administered, allowing the drug 
to pass through intact skin over a controlled period of time to achieve a local or systemic 
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effect (2). Drugs can be delivered through transdermal patches in dissolved lipid based 
form enabling them to produce the required efficacy (7, 8).
The first transdermal system containing scopolamine was approved in the United 
States in 1979; the US Food and Drug Administration (FDA) approved nicotine patches in 
1984 (9). A decade later, transdermal patches for pain relief, analgesic activity, contracep-
tion, and hormone replacement therapy were FDA approved and marketed (10), and the 
progress in this field continues today. Table I shows some transdermal patch products 
currently on the US market (2, 9, 11–13).
Transdermal drug delivery systems evade a variety of issues associated with other 
routes of drug administration, such as first-pass hepatic metabolism, enzymatic digestion, 
drug hydrolysis in acidic environments, gastrointestinal irritation, drug fluctuations, ad-
verse effects and therapeutic failure, and disease transmission risk. Further advantages 
include patient compliance, low cost, and controlled drug release (14). Limitations to trans-
dermal drug delivery include the possibility of skin irritation, macromolecular agents and 
that ionic drugs cannot be delivered, and it is not suitable for patients in shock or with low 
peripheral blood flow (14, 15). Classification of transdermal drug delivery systems has 
proceeded through three generations on the basis of drug molecule size and the presence 
Table I. Drug product and clinical use of transdermal patches on the current market
Drug Product name Clinical use
Scopolamine Transderm-Scop Motion sickness
Nitroglycerin Transderm-Nitro Angina pectoris
Clonidine Catapres-TTS High blood pressure
Estradiol Estraderm Menopause
Fentanyl Duragesic Chronic pain
Nicotine Nicoderm Smoking cessation
Testosterone Testoderm Testosterone low level 
Lidocaine/epinephrine Iontocaine Pain relief 
Estradiol/norethidrone Combipatch Menopause
Lidocaine Lidoderm Pain relief 
Norelgestromin Ortho Evra Contraception
Estradiol/levonorgestrel Climara Pro Menopause
Oxybutynin Oxytrol Overactive bladder
Lidocaine (ultrasound) SonoPrep Pain relief
Lidocaine/tetracaine Synera Pain relief
Fentanyl HCl Ionsys Postoperative pain
Methylphenidate Daytrana ADHD 
Selegiline Emsam Depression
Rotigotine Neupro Parkinson’s disease
Rivastigmine Exelon Dementia
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of penetration enhancer materials (11, 16). In the first generation, small drug molecules 
could be topically applied without using transdermal penetration enhancing agents. In the 
second generation, transdermal enhancing agents were added to enhance the penetration 
of topically applied small drug molecules. Macromolecule penetration was enabled in 
topically applied medication in the third generation. Physicochemical properties, chemical 
nature, strength, molecular weight, ionization degree, drug partition coefficients, and the 
hydrophile-lipophile balance (HLB) of polymers are parameters that should be considered 
in transdermal patch development (17–22).
Transdermal drug delivery systems can be modified using a number of permeation 
enhancer materials so that the drug absorption profile can be controlled in a predictable 
manner. Various transdermal drug delivery systems have different mechanisms to control 
the drug release rate, such as single layer or multilayer drugs in the adhesive system, va-
pour patch, membrane moderated, microreservoir transdermal systems, matrix systems 
containing drug-in-adhesive or matrix-dispersion systems. Therefore, the present review 
contains a brief description of various types of transdermal patches available on the mar-
ket with FDA approval, their structural components, ingredient physicochemical proper-
ties, designs, method of preparations, polymeric matrix components and various evalua-
tion methods required for the assessments. FDA approved transdermal patches available 
on the current market are described below.
TYPES OF TRANSDERMAL PATCHES
Single layer drug-in-adhesive patches
In Fig. 1, a single layer of polymer with adhesive properties is used as a reservoir for 
drug dispersion. An impermeable backing laminate is placed beneath the single layer. The 
drug is deposited in and adheres to the single polymer layer, and is released from the back-
ing laminate layer that supports the drug reservoir (23). The transdermal product Day-
trana® is an example of a single layer drug-in-adhesive transdermal patch containing 
methylphenidate.
Multilayer drug-in-adhesive patches
Multilayer transdermal patches consist of a drug reservoir layer and an adhesive 
layer where drug release is controlled over a period of time (24–25). A temporary protec-
tive layer and a permanent backing laminate are included in multilayer systems. Multi-
layer patches are used to deliver pain medication, drugs that encourage smoking cessation, 
and hormone therapy; drug delivery can be prolonged for up to seven days.
Vapor transdermal patches
Vapor transdermal patches consist of a single layer of adhesive polymer with a vapor 
release property where vapor can be released (24–25). A number of vapor dermal patches 
are available on the market and are used for different purposes. For example, nicoderm 
CQ® are nicotine vapor transdermal patches containing essential oils that, when released, 
can help quit smoking. This product was introduced to the European market in 2007. Al-
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tacura® vapor patches are another type of vapor patches containing essential oils that can 
be used in cases of decongestion. Another type of vapor patches as anti-depressant medi-
cations or sedatives are also available on the market (Table I).
Membrane moderated transdermal reservoir patches
Fig. 1 shows a transdermal patch containing a drug reservoir, a backing layer made of 
impermeable metallic plastic laminate, and a porous polymeric membrane that controls 
drug release over time. The membrane is made of polymeric materials (e.g., hypoaller-
Fig. 1. Schematic diagram of various types of transdermal patches.
genic adhesive polymer, ethylene vinyl acetate copolymer). Drug in the transdermal patch 
is controlled by molecular dispersion of the drug in a polymer matrix part of the prepara-
tion (26, 27). Commercial transdermal patches with modified drug release include Trans-
derm-Nitro® containing nitroglycerin for one-day application, Transderm-Scop® contain-
ing scopolamine for three-day application, and Catapres® containing clonidine for 
seven-day application (Table I).
Microreservoir transdermal patches
Microreservoir transdermal patches combine matrix dispersion with a drug reservoir. 
The reservoir is prepared by suspending the drug in an aqueous solution of hydrophilic 
polymer, then homogeneously dispersing the drug suspension on a lipophilic polymer. 
Dispersion is carried out with a high shear mechanical force, which results in the forma-
tion of thousands of microscopic, unleachable spheres. The drug release profile follows a 
zero order rate of kinetic drug release, maintaining a constant drug level in the plasma. 
Crosslinking polymeric agents are usually added, since the drug dispersion needs to be 
thermodynamically stable (25, 28).
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Matrix system: drug-in-adhesive
Using single layer or multilayer transdermal patches, the drug reservoir is designed 
to distribute the drug on an adhesive polymer, as shown in Fig. 1. This drug-polymer ma-
trix is placed onto an impermeable backing layer either by solvent casting or by melting 
the adhesive polymeric materials (29). A number of commercial products of this type of 
transdermal patch are available on the market; for example, the Climara® transdermal 
patch contains 100 micrograms of estradiol for one-day application, and the NicoDerm® 
CQ transdermal patch contains nicotine to encourage smoking cessation for up to 10 weeks 
(Table I).
Matrix systems: Matrix-dispersion
In a matrix transdermal patch, the reservoir is a hydrophilic or lipophilic polymer 
matrix and the drug is homogenously dispersed in the matrix (30) by placing the drug-
-polymer matrix over a plate with an impermeable laminate backing. Commercial products 
of matrix dispersion patches such as Nitro-Dur®, which contains nitroglycerin and mini-
tran, provide a continuous drug flow through intact skin (Table I).
Miscellaneous transdermal patches
Other FDA approved transdermal matrix delivery systems are transdermal patches 
with adhesive tapes, transdermal gel, transdermal spray, iontophoretic delivery, and pho-
nophoresis delivery, as shown in Table II.
STRUCTURAL COMPONENTS OF TRANSDERMAL PATCHES
Drug selection
In order to design transdermal patches, the physicochemical properties of drugs need 
to be considered. Hydrophobicity and ionization status are essential factors in drug selec-
tion as they influence skin penetration (14), determining drug solubility and diffusivity 
through the stratum corneum layer of the skin (31). Other physicochemical properties of 
the drug that have a direct effect on skin penetration are the melting point (MP), partition 
Table II. FDA approved other transdermal delivery systems
Drug Product name Transdermal delivery system
Flurandrenolide Cordran® Tape Transdermal tape
Testosterone AndroGel® Transdermal gel
Estradiol Evamist® Transdermal spray
Fentanyl HCl IONSYS® Iontophoretic patch
Insulin Vyteris insulin patch® Iontophoretical patch 
Hydrocortisone Tegaderm patch Electrophotophoresis
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coefficient (log P), aqueous solubility, molecular size and molecular weight (MW), dose 
concentration and saturation, permeability, absorbability, and diffusivity across the stra-
tum corneum of human skin (32–33). Most transdermal patches contain lipophilic drugs, 
that is, above the lower Berner–Cooper boundary of MW = 500, < 1000 Daltons, log P range 
from 1 to 5, and MP < 250 °C. For example, fentanyl has moderate MW (337 Da), low MP 
(83 °C), and moderate to high lipophilicity (log P = 3.9) (9). Drugs with low dose strength, 
short half-life, facile hydrolysis in acidic media, and those subject to hepatic metabolism, 
can evade the above mentioned issues when delivered by transdermal patches (24, 32, 33).
Polymer matrix characteristics
Polymers control the drug release rate from the drug reservoir in the transdermal 
patch, allowing a safe, constant, and effectual drug delivery to the body (34). Companies 
that market transdermal patches often focus on the development of a specific polymeric 
system. Alza Corporation specializes in microporous polypropylene and ethylene vinyl 
acetate (EVA) copolymers. Searle Pharmacia emphasizes silicone rubber (35, 36). Sigma 
fabricates isosorbide dinitrate matrixes using ethylcellulose. Colorcon, in the United King-
dom, employs hydroxypropyl methylcellulose (HPMC) in matrix preparation for propran-
olol transdermal delivery (37).
Table III. Transdermal patch composition
Polymer Drug Type of system Reference
HPMC Propranolol Matrix 39
HPMC Hydrocortisone Gel 40
Silicone elastomers (MDX4-421) l-Timolol maleate Matrix 41
Carboxy vinyl l-Dopa Gel 42
Acrylic adhesives Tacrine Drug-in-adhesive 43
Ethyl cellulose T-50 Isosorbide dinitrate Matrix 44
Cariflex TR-1107 Dihydroetorphine Drug-in-adhesive 45
Acrylic PSA Nicotine Drug-in-adhesive 46
HPMC Nicorandil Reservoir 47
HPMC Nimodipine Membrane moderated 48
HPMC/ Eudragit RL100 Carvedilol Reservoir 49
HPMC/ Chitosan Etoricoxib Matrix 50
Acrylic adhesives Rivastigmine Drug-in-adhesive 51
DURO-TAK® adhesives Indapamide Drug-in-adhesive 52
HPMC/ MC/ PVP Celecoxib Matrix 53
Acrylic adhesives Meloxicam Drug-in-adhesive 54
HPMC/ PVP/ CP Glibenclamide/ Atenolol Matrix 55
Acrylic / Silicone polymer Diclofenac Diethylamine Drug-in-adhesive 56
HPMC – hydroxypropyl methyl ether; MC – methyl cellulose; PVP – polyvinylpyrrolidone; CP – carbopol 
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Polymers in transdermal patch matrix formation
Polymers employed in transdermal patch formulation have various functions, such as 
matrix formation, drug delivery rate control, pressure sensitive adhesives, backing lami-
nates, and protective drug release liners. They should be biocompatible with the skin, and 
should render a constant and effectual supply of the drug throughout the delivery period 
advertised by the manufacturer (38). Polymer use in transdermal patch formulations and 
the corresponding references are shown in Table III.
Polymer selection is critical in the design of a polymer matrix because the polymer af-
fects the release properties of the drug, the adhesion/cohesion balance, and the stability of 
the product and its compatibility with other product constituents and the skin of the recipi-
ent (57). Several polymers used in transdermal patch matrix formation are described below. 
Polyethylene glycol. – Polyethylene glycol (PEG) has a wide range of biomedical applica-
tions because PEG has excellent biocompatibility. The polymeric network obtained by 
crosslinking PEG with tris(6-isocyanatohexyl)isocyanurate, with the help of the aurethane-
-allophanate bond, has the ability to swell and form gels in phosphate buffered ethanol or 
saline. This system releases solutes in a biphasic mode (58).
Acrylic-acid matrices. – Acrylic acid matrices along with plasticizers are widely used in 
the fabrication of the drug polymer matrix for transdermal patches. Examples of such 
polymers are Eudragit S100, Eudragit E100, Eudragit RS PM, and Eudragit RL PM (59). 
Eudragit NE 40 D, a nonadhesive copolymer of ethyl acrylate and methyl methacrylate, is 
used as a matrix forming agent in transdermal patches (60).
Cellulose derivatives. – Ethyl cellulose and polyvinylpyrrolidone (PVP) with dibutyl 
phthalate (30 %) as a plasticizer matrix have been used to fabricate diltiazem HCl and in-
domethacin patch systems. To improve the drug release rate, a water soluble polymer such 
as PVP is added to water insoluble films to form polymers such as ethyl cellulose. The high 
drug release rate is due to the leaching of water soluble constituents, which results in pore 
formation (61).
Hydroxypropyl methylcellulose (HPMC). – HPMC is a water soluble polymer that swells 
by absorption of water. It is widely used in oral controlled release drug delivery systems. 
It has been tested as a matrix forming agent for propranolol transdermal formulations. 
HPMC forms clear films, since the drug is very soluble in the polymer. HPMC matrices 
show fast drug release due to the burst effect during dissolution testing. This is attributed 
to the easy hydration and swelling of the polymer in the matrices (39). 
Pressure sensitive adhesives (PSA). – Adhesive characteristics of transdermal patch prepa-
rations are crucial to transdermal devices. There should be a complete and intimate contact 
between the patch and skin surface for efficient delivery of the drug. This contact is attributed 
to interatomic and intra-molecular attractive forces that PSAs establish with the skin (60). 
PSAs are viscoelastic chemical substances that adhere to the skin with low pressure applica-
tion (62). PSAs need to deform under pressure to attain the required degree of contact (63). 
PSAs adhere to the skin with no more than applied finger pressure, they are aggressively 
and permanently sticky, they exert a strong holding force, and they can be removed from 
a smooth surface without leaving a residue. Most adhesives used in transdermal patches 
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are polyisobutylene, acrylic, and silicone based (63). Adhesion is enabled by a liquid-like 
flow of adhesive material that wets the skin surface when pressure is applied. Adhesion 
takes place when elastic energy is stored during the bond breaking process. Hence, visco-
elastic materials have the characteristics of pressure sensitive adhesion, and it is the balance 
between elastic energy and viscous flow that determines the practicability of the material 
(35). Natural rubber, acrylics, thermoplastic elastomers, polyisobutylene, and silicone 
based adhesives are generally used in transdermal patch designs (64). The choice of a suitable 
adhesive involves factors such as drug formulation, patch design, and compatibility with 
other patch constituents and the skin (35). Polyacrylics are water soluble, biodegradable, 
polyester based polymers formed by the polymerization of an alkyl acrylate ester. Poly-
acrylics are widely used in the pharmaceutical industry, especially as adhesives in the 
preparation of transdermal patches. They form liquids at pH 5 and gels at pH 7 (65). Their 
mechanical characteristics improve as their molecular weight increases (63). Polyisobutylene 
(PIB) is a vinyl polymer formed by the cationic polymerization of an isobutylene monomer. 
PIB is a colorless, semisolid elastic substance with very low moisture and air permeability. 
It has good thermal and oxidative stability (66). Its physical characteristics change with 
an increase in molecular weight. Low MW polymers are less viscous than high MW 
 polymers (35). Pressure sensitive adhesives are gaining more importance because they are 
solvent free, environmentally friendly, and are easy to produce. They are prepared from 
thermoplastic materials, plasticizers, and Escorez™ tackifying resins. They are suitable for 
the fabrication of matrix patches owing to their high drug loading capacity and strong 
cohesiveness (67).
Rate controlling membrane. – In a transdermal patch, the active agent diffuses through 
an inert membrane at a finite and controlled rate. The dosage rate per patch area is con-
trolled by altering the composition and thickness of the inert membrane (35).
Ethylene vinyl acetate (EVA). – Ethylene vinyl acetate (EVA) is often used to prepare rate 
controlling membranes for transdermal patches. The permeability of the membrane can 
be altered by adjusting the percentage of vinyl acetate in the polymer (35). 
Silicone rubber. – Silicone rubber is an elastomer (rubber-like material) composed of 
silicone, itself a polymer, along with carbon, hydrogen, and oxygen. It is often used in rate 
controlled devices because it is biocompatible, easily obtained, and permeable to many 
drugs, especially steroids. The high permeability of steroids is due to free rotation around 
the silicone rubber backbone which is responsible for the low microscopic viscosity in the 
polymer (35).
Polyurethane. – Polyurethanes (PU) are polymers formed by the condensation of polyols 
(organic compounds containing multiple hydroxyl groups) and urethane. Polyurethanes 
made from polyester and polyols are called polyester urethanes whereas polyurethanes 
made from polyether and polyols are called polyether urethanes. Because of their resistance 
to hydrolysis, most urethanes used in transdermal patches are polyether urethanes (35). 
However, polyester urethanes have gained attention due to their biodegradable nature 
(35). Urethane polymers are rubbery and permeable. Their permeability can be increased 
by adjusting the hydrophilic and hydrophobic ratios of the incorporated polymers (68). 
Polyurethane membranes are suitable for passing hydrophilic compounds, which have 
low permeability in hydrophobic silicone or EVA membranes (69).
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Release liner. – A transdermal patch is covered with a layer of protective material, which 
is removed immediately before the patch is applied to the skin. This layer is a part of pri-
mary packaging (38). Because of intimate contact of the liner with the dosage form, it should 
also meet all the requirements concerning the inertness to the constituents of the delivery 
system and penetration properties (41). Fluorpolymers, fluoroolefin-based polymers, and 
linear fluoroacrylates are commonly used to manufacture a release liner; e.g., BIO PSA 
HighTack 7-4301, BIO PSA MediumTack 7-4201, Scotch Pak 1022, Scotch Pak 1006 (70, 71).
Backing laminate. – The material of the backing layer should be chemically resistant 
and inert to other constituents in the delivery system. Furthermore, it should hinder the 
leaching of additives. An efficient backing layer is flexible and facilitates the transmission 
of oxygen and moisture. Examples include silicone oil, EVA, Polyisobutylene, 3M Scotch-
pak Backing 1006 (72).
Penetration enhancers. – Stratum corneum offers the main barrier function of the skin 
(73). Penetration (or permeation) enhancers are chemical compounds that efficiently and 
reversibly weaken the stratum corneum barrier properties, allowing drugs to penetrate to 
deeper layers of the skin and reach the systemic circulation (74). Many chemical com-
pounds have been tested in order to discover more efficient and inert permeation enhancers 
to employ in transdermal patches. About 360 chemical compounds have known permea-
tion enhancing ability (75), and skin permeability is enhanced by many different mechanisms. 
Some chemicals interact with the skin and solubilize lipids within the stratum corneum, 
others hydrate the stratum corneum, and many others increase the fluidity of intercellular 
lipids in the stratum corneum. Increased fluidity in the stratum corneum results in increased 
skin permeability (76). Permeation enhancing compounds include terpenes, sulphoxides, 
pyrrolidones, laurocapram, fatty acids, alcohols, fatty alcohols, surfactants, glycols, urea, 
and bile salts (77–79).
Other excipients. – Solvents used in transdermal patch preparation include methanol, 
ethanol, dichloromethane, and acetone. Solvents are used in the drug reservoir. Plasticizers 
such as dibutylpthalate and triethylcitrate are used in concentrations ranging from 5–20 % 
(80, 81) to add plasticity to transdermal patches (80). Phosphate esters and glycol derivatives 
(polyethylene glycol, propylene glycol) are also used for plastification of the polymeric 
films in transdermal patches (81).
CHARACTERIZATION AND ASSESSMENT TOOLS FOR TRANSDERMAL 
PATCH PREPARATION
A number of assessment and evolution tests should be performed in order to descript 
and characterize transdermal patches such as dissolution, in vitro drug release, in vitro skin 
permeation, adhesive properties and control of excipients. These tests are mentioned below 
and they comply with the European Medicines Agency Guidelines on the quality of trans-
dermal patches made by the Committee for Medicinal Products for Human Use (82). Moreover, 
other types of physical, chemical and biological tests, evaluation and assessments explained 
below should be performed such as interaction of materials, patch thickness, weight uniformity, 
folding endurance, moisture content, moisture uptake or weight gain, water vapor permea-
bility, drug content, flatness, stability, swellability and  skin irritation tests.
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Drug-polymer interaction studies
Interactions between drugs and polymers in a lipid matrix can be determined using 
a number of thermal and physico-analytical techniques (82–84), such as differential scan-
ning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), X-ray powder 
diffractometry (XRPD), nuclear magnetic resonance (NMR) spectroscopy, and infrared 
(IR) radiation. Identification of components in a eutectic drug-polymer mixture is possible 
because each chemical has a unique peak in DSC, IR, and NMR spectra. To observe interac-
tions between cell surface and polymer, a florescence agent is attached to the polymer, the 
complex is incubated with cells, and the polymer-cell complex is visualized under a confocal 
microscope. NMR can be used to clarify the effect of the polymer on lipid membrane 
 fluidization/stabilization.
Patch thickness
Patch thickness is calculated by taking readings at three to five places on the patch 
with a digital micrometer screw gauge. Mean thickness and standard deviation of such 
multiple readings are determined to make sure that patch thickness is appropriate (85, 86).
Weight uniformity
Weight uniformity is determined by weighing 10 individual, randomly selected 
patches, and calculating the average weight and standard deviation. Individual patch 
weight must not vary to a large extent from the average weight (87).
Folding endurance
When a particular area of patch is sliced evenly and repeatedly folded at an identical 
point until it breaks, folding endurance is the number of times the film is folded without 
breaking (85).
Moisture content
To calculate the moisture content of a transdermal patch, the patch is accurately 
weighed, placed in a desiccator with fused calcium chloride for 24 h and then reweighed 
(87). Percentage of moisture in the patch is calculated using the following equation (1):





  100´  (1)
Moisture uptake or mass gain (88)
Mass gain in a transdermal patch usually signifies moisture uptake. To measure moisture 
uptake, the patch is weighed, placed in a desiccator with a saturated KCl solution, and 
incubated up to 24 h with RH maintained at about 84 %. The patch is then reweighed and 
moisture uptake is calculated using equation (2).
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  100´  (2)
Evaluation of water vapor permeability
A natural air circulation oven is used to determine water vapor permeability (WVP) 
in a patch, where:
 WVP = W/A (3)
where water vapor permeability is expressed in g m–2 per 24 h, W = amount of water vapor 
(g per 24 h) permeated in the patch, and A is the surface area (m2) exposed on the patch 
sample (89).
Drug content
To measure the drug content of a transdermal patch, a specific area of the patch is 
dissolved in a specific volume of a selected solvent. The solution is shaken continuously 
for up to 24 h, ultrasonicated for a specific period of time and then filtered. Drug content 
in the filtrate is determined using an appropriate analytical method (87).
Flatness test
A transdermal patch is cut into three longitudinal strips: one from the right side, one 
from the left side, and one from the center. The length of each strip is measured (90). The 
following equation is used for flatness determination:
 Constriction (%) = (I1 – I2) × 100 (4)
where I1 = strip initial length,  I2 = strip final length.
Stability studies
Prepared transdermal patches are stored for six months at 40 ± 0.5 °C and RH of 75 ± 
5 %. After the six-month storage, the samples are taken out of storage at intervals of 0, 30, 
60, 90, and 180 days and analyzed to determine the drug content (91).
Determination of adhesive properties 
Adhesive properties can be characterized using a number of tests such as peel force 
tests, adhesive strength tests and tack tests. In vitro and in vivo tests can be used to charac-
terize the adhesive properties of the drug in a transdermal preparation (82).
Tack properties
Tack is the ability of a given polymer to stick to a substrate when light pressure is 
applied. Tack depends on the composition and the molecular weight of the polymer.
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Probe tack test
The force required to pull a probe, far from the adhesive polymer at a fixed rate, is 
measured as the value of tack. The probe tack test can be used to replace the thumb test to 
determine the amount of force required to break the bond of the surface of a pressure 
sensitive adhesive in a transdermal patch (92). The force required to break the bond over 
specific time is plotted as force vs. time.
Quick stick test/Peel tack test
This test involves pulling an adhesive tape over the transdermal patch at an angle of 
90° and a speed of 12 inches/min. The tack value is the peeling force needed for breaking 
the bond between substrate and adhesive (93).
Peel adhesion test
Peel adhesion is the force needed to remove an adhesive polymer coating from a given 
substance. To measure peel adhesion, a piece of tape is applied to a plate of stainless steel 
backing membrane and then pulled at 180° from the test substance. The force required to 
pull the tape is then measured. The test is performed to make sure that the adhesive does 
not damage the skin and that no residues are left on the skin (94).
Tensile strength
Tensile strength is measured with a tensiometer. A patch is fixed to the tensiometer 
assembly, the weight required to break the patch is determined, and the resultant elonga-
tion of the patch is measured (with the pointer on the instrument). The mean of three patch 
readings is considered to be the tensile strength of the patch (92). The tensile strength of 
the patch is:
 Tensile strength = break force / a ´ b (1 + ΔL/L) (5)
where, a = patch width, b = patch thickness, L = patch length, ΔL = patch elongation at 
breakage point, and break force = weight (kg) required for patch breakage.
Swellability
To determine the swellability of a transdermal patch, the sample is applied to a pre-
weighed cover slip in a Petri dish containing 50 mL phosphate buffer, pH 7.4. Sample 
absorption takes place during time t (usually about 30 min) (95). After time t has elapsed, 
the cover slip is removed from the Petri dish, washed and weighed. The change in mass is 
equal to the mass of water absorbed by the patch. 
Percentage swelling (S) is determined by the following equation (95).
 S (%)   
   W W
W





where S = % swelling, W0 = original mass of the patch at time zero, Wt = patch mass at time 
t after swelling.
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In vitro drug release
An in vitro drug release evaluation experiment can give reliable indication of the rate 
and extent of drug release from a transdermal patch. A number of methods can be used to 
evaluate drug release from the transdermal formulation with an appropriate, non-rate-
-limiting membrane. However, alternative methods, with improved discriminative power 
compared to the compendial methods, may be employed (82). A number of methods can 
be used to evaluate drug release from a transdermal formulation (96) and they include: i) 
the paddle over disc (USP apparatus 5/PhEur 2.9.4.1) which is similar to the USP paddle 
dissolution apparatus, except that temperature is adjusted to skin temperature (32 ± 5 °C) 
and a disc or cell containing the formulation is immersed at the bottom of the vessel; ii) the 
cylinder modified United States Pharmacopeia (United States Pharmacopeial Convention, 
Inc.) (USP) basket (USP apparatus 6 / PhEur 2.9.4.3) which is similar to the USP basket type 
dissolution apparatus method, except for a hollow cylinder immersed in medium and 
temperature maintained at 32 ± 5 °C; iii) the reciprocating disc (USP apparatus 7) method 
in which the formulation is placed into holders and oscillated in small volumes of buffer 
medium; iv) paddle over extraction cell method (PhEur 2.9.4.2) may also be used. Besides, 
diffusion cells include the Franz-diffusion cell and its modification the Keshary-Chien cell 
widely used to evaluate drug release from the transdermal formulation. 
Mathematical models that describe the kinetics of drug release from a transdermal 
patch include Higuchi, first order, zero order, and Peppas and Korsenmeyer models. After 
data are collected and introduced into these models, the model that fits the data best is 
used to determine the mechanism of kinetic drug release (97). According to the European 
Medicines Agency Guidelines on quality of transdermal patches issued by the Committee 
for Medicinal Products for Human Use, at least 3 sampling time points are recommended 
(82).
Ex vivo skin permeation studies
Ex vivo skin permeation studies might not be indicative of the in vivo release assess-
ment, but may be considered a valuable measure of product quality, reflecting the thermo-
dynamic activity of the active substance in the product. Ex vivo skin permeation studies 
should be consistent throughout the shelf-life of the transdermal preparation (82). The ex 
vivo permeation studies are performed using a vertical diffusion cell, commonly called the 
Franz diffusion cell. The ex vivo permeation assessment carried out using two compart-
ments for diffusion, an upper compartment with the diffusion area of 1.54 cm2 and an inner 
compartment with a volume of up to 10 mL (98). An animal biological membrane such as 
pig ear skin or rat’s skin can be used and placed between the two compartments for the 
permeation study. A phosphate buffer solution of pH 7.5 is usually used as acceptor medium. 
For the receptor compartment of the diffusion cell, the receptor solution is maintained at 
32 ± 0.5 °C under constant stirring using magnetic rods (99). The patch is placed between 
the upper and inner compartments mounted so that the drug releasing surface faces the 
receptor side. The inner compartment buffer medium is subjected to continuous stirring 
at a constant rate. Samples of about 500 µL are usually taken over specific intervals. When 
a sample is taken, it is replaced with a similar volume of buffer. Collected samples are 
further diluted and measured using a proper analytical HPLC method. Drug permeation 
is measured at regular intervals, and volume vs. time plots are constructed.
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Skin irritation study
Skin irritation potential of different transdermal patches can be evaluated either by 
visual inspection of erythema and edema using the PII test or examined microscopically 
by a light microscope for any histopathological changes. Albino rats of average weight up 
to 230 g can be used to test transdermal patches for skin irritation. Patches applied over an 
area of 8.1 cm2 of the rat back after it is cleaned with rectified spirit and shaved 24 h prior 
to the experiment (100). The patch is applied for 24 h, then removed and the area is cleaned 
with a disinfectant swab. Inspection is carried out visually on the sites of application for 
any possible changes in terms of skin erythema and edema. Draize scale can be used to 
score the changes involving erythema and edema between 0 and 4 (101). This is rated based 
on the degree of severity of skin reactions (101). PII is calculated according to the following 
equation:                                                             
PII= {Sum of erythema grade on many days + Sum of edema grade on a number of 
days}/Number of animals (102).
CONCLUSIONS
On the basis of the obtained review, this article provides valuable literature on trans-
dermal patches, structural components, characterization and assessment tools required 
for the preparation, development and clinical performance of the various types of patches. 
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